Skip to main content
TLSA logo

Tiziana Life Sciences Ltd (TLSA) Stock Price & Analysis

Tiziana Life Sciences Ltd (TLSA) — MoonshotScore 32/100 (Weak band), calculated Nov 18, 2026. Price $0.6206 (-8.14%), as of the Nov 20, 2026 trading session; market cap $79.5M.

Educational signal · not a buy or sell recommendation · How to read this

$0.6206 −$0.055 (-8.14%) Market Cap $79.5M

Tiziana Life Sciences Ltd · TLSA · NASDAQ

Tiziana Life Sciences Ltd is a biotechnology firm focused on developing innovative therapies for oncology and immunology. With a strong pipeline including Foralumab and Milciclib, the company aims to address significant unmet medical needs.

Price as of Nov 20, 2026

Key Statistics

32 of 100

MoonshotScore v2 · Tiziana Life Sciences (TLSA)

Weak
Business Quality Average (52)
Financial Safety Strained (28)
Valuation Rich (39)
Growth Durability Fading (34)
Momentum Slipping (29)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

A strained balance sheet, weak growth and an expensive valuation, though quality is only middling, and the price trend has turned against it. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone. Business Quality: Average; Financial Safety: Strained; Valuation: Rich; Growth Durability: Fading; Momentum: Slipping.

  • Altman Z -11.77 · Piotroski F 1

Holding back: balance-sheet strain, soft growth, weak price trend

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for TLSA (53 recorded, newest six shown)
RecordedScoreBand
31Weak
31Weak
31Weak
32Weak
32Weak
32Weak

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$0.6206
Change on the day-8.14%
52-week range$0.5503 – $1.90
Market capitalisation$79.5M—
Shares traded on the day231.2K

Price & events

Other perspectives

Council score for Tiziana Life Sciences (TLSA): perspectives

Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.

5-Factor Breakdown

Business Quality Neutral
Financial Safety Weak
Valuation Weak
Growth Durability Weak
Momentum Weak

Legends Council

2 lenses, 2 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Moon AI lens (model) Neutral read

Read on: Nov 20, 2026

Munger's Mindset

Balance Sheet & Valuation

Financial Health Weak
Margin of Safety Fairly Valued
Profit Margin Weak
ROE Negative
Gross Margin Negative

Read on: Nov 20, 2026

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

One of these lenses reads this company more favourably than the MoonshotScore does: Dalio-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.

The Munger lens reads the current price as fairly valued against its own estimate of value.

Readings on this page are from Nov 21, 2026, except a card that shows its own read date.

1 · What is it?

What is Tiziana Life Sciences (TLSA), and what does it report?

Short answer

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Tiziana Life Sciences Ltd (TLSA) is listed on NASDAQ. It employs 10 people and is led by Ivor R. Elrifi. The market values it at $79.5M.

3 · Financial strengths and risks

What are the financial strengths and risks for Tiziana Life Sciences (TLSA)?

Short answer

What is holding it back is balance-sheet strain, soft growth, weak price trend. The distress and quality screens read Altman Z -11.77 · Piotroski F 1. Trailing ratios: current ratio 0.69.

Data-derived red flags

  • Listing risk — at $0.6206 the shares sit below the $1.00 minimum bid NASDAQ requires for continued listing.
  • Financial-distress signal — its Altman Z-Score of -11.77 sits in the distress zone (elevated bankruptcy risk).
  • Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
4 · What to check next?

What should you watch next at Tiziana Life Sciences (TLSA)?

Short answer · as of

Analyst estimates on file carry FY2026 revenue $0.00 · EPS -0.17 · 0 analysts.

What the records here don't tell us

  • The next earnings date is not yet scheduled in the calendar we read.
  • No insider Form 4 transaction falls inside the window this page reads.
  • No quarterly income statement is held for TLSA.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does Tiziana Life Sciences compare with its peers?

Short answer

Tiziana Life Sciences's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Regeneron Pharmaceuticals, Inc. (REGN) Named competitor$923.34 Nov 19, 2026$95.5B95 5-pillar Nov 18, 2026
Fennec Pharmaceuticals Inc. (FENC) Same industry, near in market value$13.45 Nov 19, 2026$475M91 5-pillar Nov 18, 2026
Zevra Therapeutics, Inc. (ZVRA) Same industry, near in market value$8.76 Nov 20, 2026$521M91 5-pillar Nov 18, 2026
Protalix BioTherapeutics, Inc. (PLX) Same industry, near in market value$2.90 Nov 20, 2026$245M90 5-pillar Nov 18, 2026
Bristol-Myers Squibb Company (BMY) Named competitor$58.80 Nov 20, 2026$120B85 5-pillar Nov 18, 2026
Amgen Inc. (AMGN) Named competitor$438.82 Nov 19, 2026$237B84 5-pillar Nov 18, 2026
Novartis AG (NVS) Named competitor$151.22 Nov 19, 2026$286B82 5-pillar Nov 18, 2026
Rallybio Corporation (RLYB) Same industry, near in market value$15.52 Nov 19, 2026$86.9M82 5-pillar Nov 18, 2026
ImmuCell Corporation (ICCC) Same industry, near in market value$10.92 Nov 20, 2026$99.3M82 5-pillar Nov 18, 2026
Gilead Sciences, Inc. (GILD) Named competitor$166.53 Nov 19, 2026$207B72 5-pillar Nov 18, 2026
Oramed Pharmaceuticals Inc. (ORMP) Same industry, near in market value$3.69 Nov 19, 2026$160M72 5-pillar Nov 18, 2026
Compugen Ltd. (CGEN) Same industry, near in market value$1.84 Nov 20, 2026$174M69 5-pillar Nov 18, 2026
Tiziana Life Sciences (TLSA) — this page$0.6206$79.5M32

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

The records behind this page

Analyst targets & estimates

What analysts have on file

Revenue estimate
$0.00
EPS estimate
$-0.17

Measured against a quoted price of $0.6206 (as of Nov 20, 2026).

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held TLSA in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported TLSA in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Tiziana Life Sciences (TLSA)?

Read these with our analysis →

Common Questions About TLSA

These answers are editorial: 1 of these 9 answers is drawn from the TLSA research dossier (written Jun 14, 2026 by gpt-4o-mini); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.

What does the MoonshotScore mean for TLSA?

TLSA carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. Tiziana Life Sciences Ltd is a biotechnology firm focused on developing innovative therapies for oncology and immunology.

Is TLSA a good stock to buy?

Stock Expert AI does not rate TLSA buy, sell or hold. Tiziana Life Sciences Ltd carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the TLSA stock price today?

The last price recorded for Tiziana Life Sciences Ltd (TLSA), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What do analysts say about TLSA stock?

Analysts generally view Tiziana Life Sciences Ltd as a high-risk, high-reward investment due to its early-stage product pipeline and the lack of current revenue.

What are the key factors to evaluate for TLSA?

Tiziana Life Sciences Ltd (TLSA) holds a MoonshotScore in the low range. No dividend yield reflects a focus on reinvesting profits into research and development. Not financial advice.

How frequently does TLSA data refresh on this page?

TLSA's price is the last quote we recorded, from the Nov 20, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven TLSA's recent stock price performance?

Tiziana Life Sciences Ltd (TLSA) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative pipeline with multiple therapeutic candidates. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider TLSA overvalued or undervalued right now?

Tiziana Life Sciences Ltd (TLSA) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

How do I research TLSA before investing?

Before investing in Tiziana Life Sciences Ltd (TLSA), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Machine-generated analysis by Stock Expert AI — model gpt-4o-mini, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 14 figures on this page — 4 from Financial Modeling Prep (FMP), 9 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.